Business · 18/09/2026
FDA Publishes Draft Strategy Document for Biosimilar User Fee Act III Post-Workshop
The Food and Drug Administration (FDA) has released a draft strategy document outlining future needs for the development of interchangeable products following a recent workshop, as part of the Biosimilar User Fee Act III (BsUFA III)
Source: Federal Register — Health and Human ServicesOpen original release →